NCT02491697View on ClinicalTrials.gov

Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2033

Conditions
Breast Cancer
Interventions
BIOLOGICAL

DC-CIK Immunotherapy

DC-CIK cells are used to treat advanced breast cancer with capecitabine.

DRUG

Capecitabine Monotherapy

All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER